Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Circling Back On Axsome Therapeutics
06:46pm, Tuesday, 02'nd Mar 2021
Axsome Therapeutics has been active in presenting its accomplishments in 2020 in recent days, making it a good time to update our investment thesis on this biopharma.
Axsome's (AXSM) Q4 Earnings Miss Estimates, Pipeline in Focus
10:37am, Tuesday, 02'nd Mar 2021
Axsome (AXSM) reports wider-than-expected loss in the fourth quarter of 2020. The company files an NDA for AXS-05 to treat major depressive disorder.
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q4 2020 Results - Earnings Call Transcript
04:19pm, Monday, 01'st Mar 2021
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q4 2020 Results - Earnings Call Transcript
Axsome Therapeutics to Present at Upcoming Investor Conferences
07:00am, Friday, 19'th Feb 2021
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorder
Forget Bitcoin: This Biotech Stock Is a Better Buy in 2021
06:00am, Wednesday, 10'th Feb 2021
This company presents much more attractive prospects than the cryptocurrency.
Biotech Bonanza: COVID Launches Science at Warp Speed
07:41pm, Wednesday, 03'rd Feb 2021
From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.
Is It Too Late to Get In On This Millionaire-Making Stock?
07:05am, Wednesday, 27'th Jan 2021
While it's already made some people rich, Axsome Therapeutics is just getting started.
Are Biotech Stocks a Good Idea Right Now?
10:22am, Thursday, 21'st Jan 2021
Take a look at a few trending biotech stocks and decide if this is something you want to invest in.
Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options
09:47am, Thursday, 07'th Jan 2021
Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.
Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study
10:41am, Monday, 04'th Jan 2021
Axsome (AXSM) posts favorable data from the long-term phase III study evaluating AXS-07 for acute treatment of migraine. The company also begins a second phase III study on AXS-05 for AD agitation.
Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer's Disease Agitation
06:15am, Thursday, 31'st Dec 2020
ACCORD is the second pivotal trial of AXS-05 in Alzheimer's disease agitation
Over 21,000 migraine attacks treated with AXS-07
Several High Impact Catalysts For Axsome In H1 2021
07:51am, Wednesday, 23'rd Dec 2020
The second half of 2020 has been pretty dull in terms of AXSM trading relative to the first half. Several positive readouts in H2'20 provided only a modest boost but set the stage for a H1'21 readout
68 % reduction in MADRS Suicidality Item score by Week 1, and 82% reduction by Week 4
Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression
06:00am, Wednesday, 02'nd Dec 2020
R apid and substantial i mprovement in depressive symptoms achieved by 44 % of patients at 2 weeks, 67 % at 6 weeks (MADRS response) , and sustained with long-term treatment
